The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension
Katerina Larissi(Children's Hospital Agia Sophia), Ersi Voskaridou(Laiko General Hospital of Athens), Christos Poziopoulos, Marianna Politou(National and Kapodistrian University of Athens), Evangelos Terpos(National and Kapodistrian University of Athens), Ioannis Papassotiriou(National and Kapodistrian University of Athens), Pagona Flevari, Alexandra Margeli(National and Kapodistrian University of Athens)
Cited by 23
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
|Journal of Clinical Oncology|2010|409
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
|Leukemia|2017|356
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320